Goldman Sachs Says Alexion Pharmaceuticals Buy Rating Predicated On Favorable Setup Heading Into FY17 As Co. Has Less U.S. Govt Exposure; However, SEC News Introduces Overhang And Looks For Additional Clarity In Coming Weeks